Cuibo Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cuibo Lin has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- An Lin
Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, China
1 shared publication Bin Liu
Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
1 shared publication- Bin Liu
Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China
1 shared publication - Chuanpeng Dong
Department of Genetics, Yale University School of Medicine, New Haven, Connecticut
1 shared publication - Chunxia Zhang
Institute of Genetics and Developmental Biology, Chinese Academy of Sciences
1 shared publication - Evangeline Li
Rutgers University, The State University of New Jersey, New Brunswick, NJ, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
Neoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial
Lin J, et al. J Gynecol Oncol. 2026 ;37:e70. https://doi.org/10.3802/jgo.2026.37.e70
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (4)
Open AccessNeoadjuvant therapy of iparomlimab and tuvonralimab combined with chemotherapy-extenuated for locally advanced cervical cancer (NICE-CC): an investigator-initiated, multicentre, open-label, phase II trial
Lin J, et al. J Gynecol Oncol. 2026 ;37:e70. https://doi.org/10.3802/jgo.2026.37.e70
- Open Access
- 6 June 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-11
The clinical practice and outcomes of minimally invasive surgery in primary malignant melanoma of the vagina and cervix patients: a retrospective cohort study
Background: Primary malignant melanoma of the vagina (PMMV) and cervix (PMMC) are extremely rare tumors with a poor prognosis, lacking well-defined protocols or standardized treatment guidelines. While the preferred management for early-stage PMMV and PMMC is surgery, comprehensive reports on the impact of various surgical techniques on cancer outcomes are scarce. Objective: This study aimed to compare outcomes between open and minimally invasive surgery (MIS) in PMMV and PMMC, and concurrently evaluated prognostic risk factors for these conditions. Methods: We conducted a single-center retrospective cohort study of PMMV and PMMC patients treated surgically from January 2000 to July 2021. Clinicopathological features and surgical outcomes were assessed retrospectively. Patients underwent either open surgery or MIS. Disease-Free Survival (DFS) rates were compared. Results: Of 45 eligible patients, the MIS group showed a higher rate of total vaginectomy (P = 0.022), reduced median intraoperative blood loss (P = 0.031), shorter median hospital stay (P = 0.042), and no significant increase in perioperative complications (P = 0.867). The incidence of negative margins < 1 cm was significantly lower in the MIS group (P = 0.032). Cox proportional hazards regression identified microsatellites (HR = 2.893 [1.042–8.029]; P = 0.042), surgical negative margin distance (HR = 0.042 [0.008–0.217]; P < 0.001), and total vaginectomy (HR = 0.042 [0.008–0.217]; P < 0.001) as independent prognostic factors for DFS. MIS was linked to a significant difference in 2-year DFS (P = 0.030), but there was no notable difference in overall survival (OS) compared to open surgery (P = 0.078). The outcomes are validated through sensitivity analysis and hierarchical assessment, leading to the development of a novel nomogram simultaneously. Conclusions: Total vaginectomy may improve DFS in PMMV and PMMC patients. A combination of MIS and radical vaginal resection can effectively manage PMMV and PMMC as an initial surgical strategy.
- 6 June 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-11
Open AccessThe clinical practice and outcomes of minimally invasive surgery in primary malignant melanoma of the vagina and cervix patients: a retrospective cohort study
Background: Primary malignant melanoma of the vagina (PMMV) and cervix (PMMC) are extremely rare tumors with a poor prognosis, lacking well-defined protocols or standardized treatment guidelines. While the preferred management for early-stage PMMV and PMMC is surgery, comprehensive reports on the impact of various surgical techniques on cancer outcomes are scarce. Objective: This study aimed to compare outcomes between open and minimally invasive surgery (MIS) in PMMV and PMMC, and concurrently evaluated prognostic risk factors for these conditions. Methods: We conducted a single-center retrospective cohort study of PMMV and PMMC patients treated surgically from January 2000 to July 2021. Clinicopathological features and surgical outcomes were assessed retrospectively. Patients underwent either open surgery or MIS. Disease-Free Survival (DFS) rates were compared. Results: Of 45 eligible patients, the MIS group showed a higher rate of total vaginectomy (P = 0.022), reduced median intraoperative blood loss (P = 0.031), shorter median hospital stay (P = 0.042), and no significant increase in perioperative complications (P = 0.867). The incidence of negative margins < 1 cm was significantly lower in the MIS group (P = 0.032). Cox proportional hazards regression identified microsatellites (HR = 2.893 [1.042–8.029]; P = 0.042), surgical negative margin distance (HR = 0.042 [0.008–0.217]; P < 0.001), and total vaginectomy (HR = 0.042 [0.008–0.217]; P < 0.001) as independent prognostic factors for DFS. MIS was linked to a significant difference in 2-year DFS (P = 0.030), but there was no notable difference in overall survival (OS) compared to open surgery (P = 0.078). The outcomes are validated through sensitivity analysis and hierarchical assessment, leading to the development of a novel nomogram simultaneously. Conclusions: Total vaginectomy may improve DFS in PMMV and PMMC patients. A combination of MIS and radical vaginal resection can effectively manage PMMV and PMMC as an initial surgical strategy.
- 17 August 2023
- Published by Springer Nature in Biochemical Genetics
- Vol. 62 (2) , 1277-1290
Knockdown of miR-24 Suppressed the Tumor Growth of Cervical Carcinoma Through Regulating PTEN/PI3K/AKT Signaling Pathway
Cervical cancer (CC) is the most prevalent malignant tumor in gynecology. Despite routine surgery, advanced CC is hard to remove completely. MicroRNA-24 (miR-24) regulates several types of tumors, but its regulatory function in CC was previously unknown. We established stable knockdown of miR-24 and phosphatase and tensin homolog (PTEN) in CC cells. We measured mRNA and protein expression with RT-PCR and western blotting. We evaluated cell proliferation, invasion, migration, and apoptosis with CCK8, Transwell, wound healing, and flow cytometry, respectively. We also examined the influence of miR-24 and PTEN on tumor growth in a metastatic tumor model in nude mice. The expression of miR-24 was significantly increased in CC tissues and cell lines (C-33A, HeLa S3, SiHa). MiR-24 inhibitor greatly suppressed PTEN/PI3K/AKT, while miR-24 mimic markedly activated this signaling pathway. Knockdown of PTEN significantly reversed the effects of miR-24 inhibitor on cell proliferation, invasion, migration, and apoptosis of CC cells. The significant inhibition effect of tumor growth and ki67 expression caused by miR-24 inhibitor was reversed by si-PTEN. MiR-24 inhibitor significantly suppressed cell proliferation, invasion, migration, epithelial-mesenchymal transition (EMT) process, and tumor growth, while promoting cell apoptosis. However, the influence of miR-24 inhibitor was markedly reversed by si-PTEN. Targeting miR-24 could provide a novel therapeutic strategy for the prevention and treatment of CC.
- 17 August 2023
- Published by Springer Nature in Biochemical Genetics
- Vol. 62 (2) , 1277-1290
Knockdown of miR-24 Suppressed the Tumor Growth of Cervical Carcinoma Through Regulating PTEN/PI3K/AKT Signaling Pathway
Cervical cancer (CC) is the most prevalent malignant tumor in gynecology. Despite routine surgery, advanced CC is hard to remove completely. MicroRNA-24 (miR-24) regulates several types of tumors, but its regulatory function in CC was previously unknown. We established stable knockdown of miR-24 and phosphatase and tensin homolog (PTEN) in CC cells. We measured mRNA and protein expression with RT-PCR and western blotting. We evaluated cell proliferation, invasion, migration, and apoptosis with CCK8, Transwell, wound healing, and flow cytometry, respectively. We also examined the influence of miR-24 and PTEN on tumor growth in a metastatic tumor model in nude mice. The expression of miR-24 was significantly increased in CC tissues and cell lines (C-33A, HeLa S3, SiHa). MiR-24 inhibitor greatly suppressed PTEN/PI3K/AKT, while miR-24 mimic markedly activated this signaling pathway. Knockdown of PTEN significantly reversed the effects of miR-24 inhibitor on cell proliferation, invasion, migration, and apoptosis of CC cells. The significant inhibition effect of tumor growth and ki67 expression caused by miR-24 inhibitor was reversed by si-PTEN. MiR-24 inhibitor significantly suppressed cell proliferation, invasion, migration, epithelial-mesenchymal transition (EMT) process, and tumor growth, while promoting cell apoptosis. However, the influence of miR-24 inhibitor was markedly reversed by si-PTEN. Targeting miR-24 could provide a novel therapeutic strategy for the prevention and treatment of CC.
- Open Access
- 18 November 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-8
Lymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study
Background: The study aims to evaluate the clinical features and management of postoperative lymphatic leakage (PLL) in patients with cervical cancer who received pelvic lymphadenectomy. Methods: This retrospective study screened consecutive patients with cervical cancer (stage Ia2-IIb). Results: Among 3427 cases screened, 63 patients (1.8%) were diagnosed with PLL, which manifested as persistent abdominal drainage (42/63, 66.7%), chylous ascites (12/63, 19.0%) or vaginal drainage (9/63, 14.3%). Median time from surgery to onset of PLL was 6 days (range, 4–21 days). All cases resolved in a median 10 days (range, 3–56 days) after conservative treatment; although one case experienced recurrence of vaginal drainage after 26 days, this also resolved after conservative therapy. Multivariate analysis showed that two cycles of neoadjuvant chemotherapy (odds ratio [OR], 3.283; 95% confidence interval [95%CI], 1.289–8.360; P = 0.013), a decrease in hemoglobin level of ≥20 and < 30 g/L (OR, 6.175; 95%CI, 1.033–10.919; P = 0.046) or ≥ 30 g/L (OR, 8.467; 95%CI, 1.248–17.426; P = 0.029), and postoperative albumin level ≥ 30 and < 35 g/L (OR, 2.552; 95%CI, 1.112–5.857; P = 0.027) or < 30 g/L (OR, 5.517; 95%CI, 2.047–18.148; P = 0.012) were associated with PLL. Conclusion: Neoadjuvant chemotherapy, postoperative anemia and postoperative hypoproteinemia are risk factors for PLL.
- 18 November 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-8
Open AccessLymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study
Background: The study aims to evaluate the clinical features and management of postoperative lymphatic leakage (PLL) in patients with cervical cancer who received pelvic lymphadenectomy. Methods: This retrospective study screened consecutive patients with cervical cancer (stage Ia2-IIb). Results: Among 3427 cases screened, 63 patients (1.8%) were diagnosed with PLL, which manifested as persistent abdominal drainage (42/63, 66.7%), chylous ascites (12/63, 19.0%) or vaginal drainage (9/63, 14.3%). Median time from surgery to onset of PLL was 6 days (range, 4–21 days). All cases resolved in a median 10 days (range, 3–56 days) after conservative treatment; although one case experienced recurrence of vaginal drainage after 26 days, this also resolved after conservative therapy. Multivariate analysis showed that two cycles of neoadjuvant chemotherapy (odds ratio [OR], 3.283; 95% confidence interval [95%CI], 1.289–8.360; P = 0.013), a decrease in hemoglobin level of ≥20 and < 30 g/L (OR, 6.175; 95%CI, 1.033–10.919; P = 0.046) or ≥ 30 g/L (OR, 8.467; 95%CI, 1.248–17.426; P = 0.029), and postoperative albumin level ≥ 30 and < 35 g/L (OR, 2.552; 95%CI, 1.112–5.857; P = 0.027) or < 30 g/L (OR, 5.517; 95%CI, 2.047–18.148; P = 0.012) were associated with PLL. Conclusion: Neoadjuvant chemotherapy, postoperative anemia and postoperative hypoproteinemia are risk factors for PLL.
- Open Access
- 25 May 2021
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 51 (8) , 1277-1286
Development and validation of a novel mRNA signature for predicting early relapse in non-small cell lung cancer
Background: Recurrence after initial primary resection is still a major and ultimate cause of death for non-small cell lung cancer patients. We attempted to build an early recurrence associated gene signature to improve prognostic prediction of non-small cell lung cancer. Methods: Propensity score matching was conducted between patients in early relapse group and long-term survival group from The Cancer Genome Atlas training series (N = 579) and patients were matched 1:1. Global transcriptome analysis was then performed between the paired groups to identify tumour-specific mRNAs. Finally, using LASSO Cox regression model, we built a multi-gene early relapse classifier incorporating 40 mRNAs. The prognostic and predictive accuracy of the signature was internally validated in The Cancer Genome Atlas patients. Results: A total of 40 mRNAs were finally identified to build an early relapse classifier. With specific risk score formula, patients were classified into a high-risk group and a low-risk group. Relapse-free survival was significantly different between the two groups in both discovery (HR: 3.244, 95% CI: 2.338-4.500, P < 0.001) and internal validation series (HR 1.970, 95% CI 1.181-3.289, P = 0.009). Further analysis revealed that the prognostic value of this signature was independent of tumour stage, histotype and epidermal growth factor receptor mutation (P < 0.05). Time-dependent receiver operating characteristic analysis showed that the area under receiver operating characteristic curve of this signature was higher than TNM stage alone (0.771 vs 0.686, P < 0.05). Further, decision curve analysis curves analysis at 1 year revealed the considerable clinical utility of this signature in predicting early relapse. Conclusions: We successfully established a reliable signature for predicting early relapse in stage I–III non-small cell lung cancer.
- 25 May 2021
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 51 (8) , 1277-1286
Open AccessDevelopment and validation of a novel mRNA signature for predicting early relapse in non-small cell lung cancer
Background: Recurrence after initial primary resection is still a major and ultimate cause of death for non-small cell lung cancer patients. We attempted to build an early recurrence associated gene signature to improve prognostic prediction of non-small cell lung cancer. Methods: Propensity score matching was conducted between patients in early relapse group and long-term survival group from The Cancer Genome Atlas training series (N = 579) and patients were matched 1:1. Global transcriptome analysis was then performed between the paired groups to identify tumour-specific mRNAs. Finally, using LASSO Cox regression model, we built a multi-gene early relapse classifier incorporating 40 mRNAs. The prognostic and predictive accuracy of the signature was internally validated in The Cancer Genome Atlas patients. Results: A total of 40 mRNAs were finally identified to build an early relapse classifier. With specific risk score formula, patients were classified into a high-risk group and a low-risk group. Relapse-free survival was significantly different between the two groups in both discovery (HR: 3.244, 95% CI: 2.338-4.500, P < 0.001) and internal validation series (HR 1.970, 95% CI 1.181-3.289, P = 0.009). Further analysis revealed that the prognostic value of this signature was independent of tumour stage, histotype and epidermal growth factor receptor mutation (P < 0.05). Time-dependent receiver operating characteristic analysis showed that the area under receiver operating characteristic curve of this signature was higher than TNM stage alone (0.771 vs 0.686, P < 0.05). Further, decision curve analysis curves analysis at 1 year revealed the considerable clinical utility of this signature in predicting early relapse. Conclusions: We successfully established a reliable signature for predicting early relapse in stage I–III non-small cell lung cancer.